Delivering a Next Generation Platform for Antibody Drug Discovery

Ablexis, LLC created and commercializes the AlivaMab Mouse technology, a unique, patented next-generation transgenic mouse platform for human therapeutic antibody discovery. Ablexis has announced non-exclusive licensing of the AlivaMab Mouse technology to multiple companies and continues making the AlivaMab Mouse available via non-exclusive licenses.

In June 2018, Deerfield Management and Ablexis signed a definitive agreement under which Deerfield Management will acquire Ablexis.

Year Invested: 2009

Recent News

June 21, 2018
Ablexis Targets Market Expansion Opportunities for AlivaMab Mouse Following Acquisition by Deerfield Management and the Founding of AlivaMab Discovery Services

September 14, 2017
Ablexis Announces Licensing of the AlivaMab Mouse to Five Prime Therapeutics

February 14, 2017
Ablexis Announces Perpetual License Agreement for AlivaMab Mouse with Janssen

Read More News

Associated Team Members

Cary Pfeffer, M.D.